ReviewThe pharmacogenomics journal2013
Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases.
Review in The pharmacogenomics journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 75 citations in OpenAlex.
- Trial
- A Common Genetic Background for Psoriasis and Cardiovascular Diseases: A Narrative Review.Health science reports · 2025Article
- Machine Learning-Driven Prediction Models for Brodalumab Therapeutic Effect and Response Speed in Plaque Psoriasis.Psoriasis (Auckland, N.Z.) · 2025Article
- Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers.Biomedicines · 2024Article
- Paradoxical psoriasis: The flip side of idiopathic psoriasis or an autocephalous reversible drug reaction?Journal of translational autoimmunity · 2023Article
- Article
- Article
- Article
- Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors.Inflammopharmacology · 2023Review
- Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis.Skin health and disease · 2022Review
- Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action.Biomedicines · 2022Review
- A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease.Frontiers in pharmacology · 2022Article
- Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.Rheumatology international · 2021Article
- Low TNFAIP3 expression in psoriatic skin promotes disease susceptibility and severity.PloS one · 2019Article
- ALPHLARD: a Bayesian method for analyzing HLA genes from whole genome sequence data.BMC genomics · 2018Article
- Genetic polymorphism in psoriasis and its meaning for the treatment efficacy in the future.Postepy dermatologii i alergologii · 2018Review
- Genetic Polymorphisms ofBioMed research international · 2018Article
- New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.The pharmacogenomics journal · 2018Article
- FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.The pharmacogenomics journal · 2017Article
- Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.The pharmacogenomics journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis (Ps) is a chronic inflammatory disease with an important genetic component. It shares pathophysiological mechanisms with other autoimmune diseases such as psoriatic arthritis (PsA), rheumatoid arthritis (RA) and Crohn's disease (CD). These conditions can be treated using biological drugs such as infliximab, adalimumab and etanercept, which selectively block the proinflammatory cytokine tumor necrosis factor (TNF)-α. Although these agents have greatly improved the prognosis of Ps, PsA, RA and CD, they do not cure the disease and are expensive; in addition, significant proportions of patients do not respond or develop serious adverse effects. Therefore, it is important to investigate biomarkers, such as gene polymorphisms, that can predict which patients will respond best to a specific drug. Some polymorphisms in genes TNF, TNF receptor superfamily 1B (TNFR1B) and TNFα-induced protein 3 gene (TNFAIP3) have been associated with response to anti-TNF therapy in patients with Ps. The present article reviews other polymorphisms that could also play a role in prediction of response to these treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.